Definitive Healthcare (NASDAQ:DH) Issues FY 2025 Earnings Guidance

Key Points

• Definitive Healthcare has issued FY 2025 earnings guidance projecting EPS between 0.220-0.230, surpassing the consensus estimate of 0.213.
• Several analysts have adjusted their ratings, with BTIG Research downgrading to "neutral," while Goldman Sachs raised its target price to $3.40.
• During midday trading, DH stock rose by 1.0%, reaching $3.97, with a market cap of approximately $590.10 million and significant institutional ownership.

Definitive Healthcare (NASDAQ:DH - Get Free Report) issued an update on its FY 2025 earnings guidance on Thursday morning. The company provided EPS guidance of 0.220-0.230 for the period, compared to the consensus EPS estimate of 0.213. The company issued revenue guidance of $237.0 million-$240.0 million, compared to the consensus revenue estimate of $237.0 million. Definitive Healthcare also updated its Q3 2025 guidance to 0.050-0.060 EPS.

Analysts Set New Price Targets

A number of research firms recently commented on DH. BTIG Research lowered Definitive Healthcare from a "buy" rating to a "neutral" rating in a research note on Friday, May 9th. The Goldman Sachs Group boosted their target price on shares of Definitive Healthcare from $3.00 to $3.40 and gave the company a "neutral" rating in a report on Monday, May 12th. Finally, Wall Street Zen upgraded shares of Definitive Healthcare from a "hold" rating to a "buy" rating in a report on Saturday, June 21st. One investment analyst has rated the stock with a sell rating, six have given a hold rating and one has assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus target price of $4.73.

Definitive Healthcare Trading Up 1.0%

DH stock traded up $0.04 during midday trading on Thursday, hitting $3.97. The company had a trading volume of 680,471 shares, compared to its average volume of 842,466. The company has a current ratio of 1.75, a quick ratio of 1.75 and a debt-to-equity ratio of 0.37. Definitive Healthcare has a 52 week low of $2.15 and a 52 week high of $5.68. The stock's 50 day moving average price is $3.87 and its 200 day moving average price is $3.63. The stock has a market cap of $590.10 million, a price-to-earnings ratio of -0.90, a PEG ratio of 6.53 and a beta of 1.64.

Definitive Healthcare (NASDAQ:DH - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.05 by ($0.03). Definitive Healthcare had a positive return on equity of 3.69% and a negative net margin of 206.05%. As a group, equities research analysts expect that Definitive Healthcare will post 0.16 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of DH. Jane Street Group LLC lifted its holdings in shares of Definitive Healthcare by 166.0% in the first quarter. Jane Street Group LLC now owns 105,114 shares of the company's stock worth $304,000 after buying an additional 65,597 shares in the last quarter. AQR Capital Management LLC increased its position in Definitive Healthcare by 56.7% during the first quarter. AQR Capital Management LLC now owns 590,149 shares of the company's stock valued at $1,706,000 after acquiring an additional 213,562 shares during the last quarter. Finally, Goldman Sachs Group Inc. increased its position in Definitive Healthcare by 564.2% during the first quarter. Goldman Sachs Group Inc. now owns 8,716,725 shares of the company's stock valued at $25,191,000 after acquiring an additional 7,404,363 shares during the last quarter. 98.67% of the stock is owned by hedge funds and other institutional investors.

Definitive Healthcare Company Profile

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.